drugset
drugset / Trial / NCT04870177

Study of AK112 in the Treatment of Advanced Gynecological Tumors

NCT04870177 ↗

Phase 2 Completed 53 enrolled Akeso
NaSingle-groupOpen-labelTreatment

Summary

A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.

Timeline

Start
2021-04-09
Primary completion
2024-05-10
Completion
2024-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody — —

Indications

endometrium neoplasm female reproductive organ cancer metastatic malignant neoplasm ovarian neoplasm uterine cervix neoplasm